Jack Dorsey Loves Twitter (TWTR); Valeant Pharmaceuticals Intl (VRX) Defies Headwinds
Twitter Inc.‘s (NYSE:TWTR) CEO Jack Dorsey disclosed in a regulatory filing ( FORM 4 ) with the U.S. Securities and Exchange Commission (SEC) that he purchased recently 63,007 shares (at an average price of $15.8715 each) and 362,991 shares (at an average price of $16.5294 each) of the social network company.
He also tweeted “#LoveTwitter” alongside a link to the SEC filing mentioned above.
TWTR stock closed at $16.52, up $0.71 (or +4.49%) and 35.09M of its shares changed hands on Tuesday’s trading session, representing a large increase in activity versus its average volume (3m) of 20.97M shares.
Twitter, which operates as a global platform for public self-expression and conversation in real time, has 714.90M shares outstanding, market capitalization (intraday) of $11.81B and TWTR stock 52-week range is from $13.73 to $25.25 per share.
Brokerage firm RBC Capital Markets reiterated a Sector Perform rating on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) stock, while reducing its price target from $29.00 to $22.00
Shares of the Canadian pharmaceutical and medical device company finished in positive territory by 6.75% (or +$1.01) at $15.98 with a total volume of 18.79M shares traded on Tuesday.
Valeant expects to present its fourth-quarter and full-year 2016 financial results on Tuesday, February 28 prior to the market opening.
Valeant Pharmaceuticals International, which develops, manufactures, and markets pharmaceuticals, OTC products, and medical devices worldwide, has 341.19M shares outstanding, market capitalization (intraday) of $5.56B and VRX stock one-year range is between $13.00 and $96.62 per share.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/